Core Viewpoint - Aethlon Medical, Inc. (NASDAQ: AEMD) is experiencing a notable increase in stock price, currently trading at $1.96, up 13% from previous levels, with a morning high of $2.09 [3][4]. Company Developments - Aethlon Medical is evaluating a range of strategic opportunities and has engaged Maxim Group LLC as its exclusive financial advisor for this process [4][5]. - The engagement with Maxim follows preliminary interest in potential strategic opportunities, including partnerships, mergers, and acquisitions [5]. - CEO James Frakes highlighted that the company is continuing its development activities, having completed the second cohort of an Australian oncology trial, with safety data to be submitted for review [6]. Product Information - Aethlon Medical is focused on the development of the Hemopurifier, a clinical-stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [9]. - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [9].

Aethlon Medical Conference Summary Company Overview - **Company Name**: Aethlon Medical - **Ticker Symbol**: AEMD (NasdaqCM) - **Industry**: Life Sciences, specifically focused on medical devices for oncology and virology Key Points and Arguments Product Description - **Lead Asset**: Hemopurifier, a medical device designed to remove harmful viruses and cancerous particles (exosomes) from the bloodstream [3][4] - **Mechanism**: The device connects to existing blood pumping mechanisms (e.g., dialysis machines) and filters blood to remove harmful particles [3][4][7] - **FDA Designation**: Received Breakthrough Device designation for life-threatening viruses and oncologic situations with no prescribed therapy [4] Clinical Focus - **Primary Focus**: Oncology, with ongoing clinical trials in Australia [4][5] - **Current Trial**: A safety trial involving three cohorts of patients, aiming to assess the Hemopurifier's effectiveness in conjunction with chemotherapy drugs like Keytruda and Opdivo [10][11] - **Market Potential**: Keytruda has a market size of approximately $25 billion, with the potential to improve treatment efficacy for the two-thirds of patients who do not respond to current therapies [12][13] Milestones and Progress - **Upcoming Milestones**: - Approval from the Data Safety Monitoring Board to proceed to the third cohort [14][15] - Data release from the second cohort and overall trial results expected in the next six months [16][24] - **Current Status**: Completed the first cohort and treated all patients in the second cohort [14][15] Financial Position - **Cash Position**: Approximately $7 million in cash with a burn rate of $1.5 million per quarter [26] - **Funding Strategy**: Engaging with investment banks for potential strategic partnerships to support the next phases of trials [34] Research and Development - **Future Applications**: Exploring the Hemopurifier's potential in treating autoimmune diseases and chronic kidney disease, while maintaining a primary focus on oncology [19][20] - **Simplified System Development**: Investigating a more user-friendly blood pumping system that could enhance the Hemopurifier's accessibility [28][29] Market Insights - **Differentiation**: The Hemopurifier is the only product that specifically removes extracellular vesicles (EVs), which could significantly improve patient outcomes in cancer treatment [50] - **High-Risk Investment**: Acknowledgment of the high-risk nature of the investment, but with potential for significant returns if successful [40] Regulatory Considerations - **Trial Location**: Conducting trials in Australia due to favorable medical practices and financial incentives, such as a reimbursement of 43% on trial costs [21][22] - **Regulatory Pathway**: Plans to apply for regulatory approval in both Australia and the U.S. upon completion of the trial [23] Additional Important Information - **Patient Treatment**: 173 Hemopurifier treatments have been conducted across 44 patients, with no serious adverse events reported [37] - **Market Opportunity**: The oncology market is vast, and even a small improvement in treatment efficacy could lead to significant patient benefits [40][48] This summary encapsulates the key aspects of Aethlon Medical's conference, highlighting the company's focus on innovative medical devices, ongoing clinical trials, financial health, and market potential.

Core Viewpoint - Aethlon Medical, Inc. (NASDAQ: AEMD) is exploring strategic opportunities with the assistance of Maxim Group LLC, which has led to a notable increase in stock price and trading volume [3][4][5]. Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier, a device aimed at treating cancer and life-threatening infectious diseases [8][9]. - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [9]. Stock Performance - The stock price of Aethlon Medical increased by 4.81%, trading at $1.7300, with a day's high of $1.94 and a trading volume exceeding 859,000 shares [3][4]. Strategic Initiatives - The company has engaged Maxim Group LLC as its exclusive financial advisor to evaluate various strategic alternatives, including partnerships, mergers, and acquisitions [4][5]. - CEO James Frakes indicated that the company is actively pursuing development activities, including the completion of the second cohort of an Australian oncology trial [6]. Clinical Development - Aethlon Medical has completed the second cohort of its oncology trial in Australia, with safety data set to be submitted for review [6].

Core Insights - Aethlon Medical, Inc. (NASDAQ: AEMD) is evaluating strategic opportunities and has engaged Maxim Group LLC as its exclusive financial advisor for this process [3][4] - The engagement with Maxim follows preliminary interest in potential strategic transactions, including partnerships, mergers, and acquisitions [4] - The company continues its development activities, having completed the second cohort of an Australian oncology trial, with safety data to be submitted for review [5] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [8] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful extracellular vesicles (EVs) from biological fluids [8] - The device is designated as a Breakthrough Device by the FDA for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [8]

Core Insights - Aethlon Medical is evaluating strategic opportunities and has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process [1] - The company has received preliminary interest regarding potential strategic opportunities, including partnerships, mergers, and acquisitions [1] - Aethlon has completed the second cohort of its Australian oncology trial, with safety data to be submitted for review [1] Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company focused on developing products to treat cancer and life-threatening infectious diseases [1] - The company is advancing the Hemopurifier, a novel platform designed to selectively remove pathogenic targets from biological fluids [1] Financial Advisory Engagement - Maxim Group LLC, founded in 2002, is a full-service investment bank providing a range of financial services, including investment banking and equity research [1] - The engagement with Maxim is part of Aethlon's ongoing efforts to assess opportunities for the company and its shareholders [1]

Aethlon Medical Conference Summary Company Overview - **Company**: Aethlon Medical (NasdaqCM:AEMD) - **Focus**: Development of medical devices for treating cancer and life-threatening infectious diseases, specifically the Hemopurifier [2][3] Key Points and Arguments Hemopurifier Device - **Description**: A medical device designed to remove infectious viruses and cancerous particles (exosomes) from the bloodstream, compatible with various blood-pumping devices [3][4] - **Primary Focus**: Oncology, particularly in patients with solid tumors who do not respond to anti-PD-1 therapies like Keytruda or Opdivo [6][10] Clinical Trials and Safety - **Historical Use**: The Hemopurifier has treated a total of 44 patients across 173 sessions, with a good safety profile and minor side effects [7][10] - **Current Study**: A safety and feasibility study involving three cohorts, with the first cohort completed successfully, and the second cohort currently in the safety follow-up phase [10][11] - **Upcoming Milestones**: Data Safety Monitoring Board meeting in March to assess the second cohort, followed by data analysis from a central lab [11][37] Regulatory and Market Strategy - **Trial Location**: Conducting trials in Australia due to favorable tax rebate programs (43% rebate) and established relationships with local investigators [12] - **Regulatory Pathway**: Plans to engage with both U.S. FDA and Australian TGA for future trials, with Breakthrough Device designations already in place [12][33] Financial Position - **Cash Position**: Approximately $7 million in cash with a monthly burn rate of $500,000, providing a runway through the current trial [30][32] - **Funding Strategy**: Access to an at-the-market offering to raise an additional $1.8 million [30] Market Potential - **Addressable Market**: The oncology market is substantial, with Keytruda alone generating $25 billion annually. Aethlon aims to carve out a niche by focusing on extracellular vesicles [35] Recruitment and Operational Changes - **Patient Recruitment**: Enhanced recruitment strategies through partnerships with Trialfacts and Dedicated, leading to a pipeline of pre-screened patients for upcoming cohorts [16][18] Competitive Differentiation - **Unique Approach**: The Hemopurifier's method of removing extracellular vesicles is distinct from traditional therapies like monoclonal antibodies and vaccines, potentially offering a cleaner safety profile [41][46] Additional Important Content - **SLAM Platform**: Early studies are being conducted to assess compatibility with a new SLAM system, which could simplify the treatment process and expand the patient base [13][15] - **Future Catalysts**: Key upcoming events include the Data Safety Monitoring Board meeting, data disclosures from the University of Sydney, and completion of the third cohort [36][38] This summary encapsulates the critical insights from the Aethlon Medical conference, highlighting the company's innovative approach, clinical progress, and strategic positioning within the oncology market.

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - Operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two patients treated in the second cohort [7][29] - The R&D team is exploring the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with Trialfacts and Dedicated [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company aims to advance the Hemopurifier platform while managing costs effectively [5] - The focus remains on the Australian oncology trial, with no plans to expand to other markets like India at this time [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the oncology trial and the potential for the Hemopurifier to serve multiple indications [11][29] - The company is committed to maintaining cost containment while advancing its research and development efforts [27] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal [10] - The next earnings call for fiscal Q4, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [18][19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive treatment method, making it easier for both hospital staff and patients [20][23] Question: Cost-effective approach in R&D - The company is focused on keeping costs down while advancing research, utilizing in-house resources as much as possible [26][27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is essential to investigate Cohort 3 to determine if three treatments could yield better results than two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before integration [46][47] Question: Future trials in India - The company is currently focused on the Australian trial and does not plan to return to India for additional trials [75][81]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two Hemopurifier treatments completed in the second cohort [7][9] - The R&D team is exploring the compatibility of the Hemopurifier with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for advertising and pre-screening [8] - The study is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its potential as a multi-indication therapeutic [5] - The integration of the Hemopurifier with the SLAMB system could facilitate its use in oncology units and infusion centers, reducing invasiveness for patients [23][24] - The company aims to build on preclinical data in Long COVID and explore other indications related to extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of cost containment while advancing clinical trials and R&D efforts [27] - The company is currently focused on completing the Australian trial and is not planning to expand to other regions like India at this time [75][78] Other Important Information - The next earnings call for the fiscal fourth quarter, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive catheter insertion, making it easier for patients and hospital staff to administer treatments [24] Question: Cost-effective approach in R&D - The company is trying to keep costs down by conducting work in-house and limiting outside lab involvement while still advancing research [27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is important to investigate the third cohort to assess the potential benefits of three treatments compared to two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before using it with the Hemopurifier [47]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [14] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control, with ongoing enrollment in the Australian oncology trial [5] - The second cohort of the oncology trial has seen two patients treated with Hemopurifier, with a third patient expected to be treated by the end of February [6][7] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for recruitment [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [5][10] - Aethlon Medical is also exploring the potential of the Hemopurifier in treating conditions beyond oncology, including Long COVID and other diseases associated with extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the Australian oncology trial and the potential for the Hemopurifier to be integrated into oncology units and infusion centers, reducing invasiveness for patients [22][24] - The company is committed to cost containment while advancing its research and development efforts, particularly in the context of Long COVID [26] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal, indicating the company's commitment to transparency and scientific rigor [10] - The next earnings call for the fiscal fourth quarter is scheduled to coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - Management confirmed that participants in Cohort 2 will receive two Hemopurifier treatments, maintaining the same follow-up period as Cohort 1 [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system is expected to simplify the administration of Hemopurifier treatments, making it less invasive for patients and easier for hospital staff [22][24] Question: Cost-effective approach in R&D - Management emphasized the importance of cost containment while advancing research, focusing on in-house work and limiting external lab involvement [26] Question: Timeline for Data Safety Monitoring Board's decision - Management anticipates a decision from the Data Safety Monitoring Board on whether to advance to the third cohort on the same day or the next business day after the meeting [34] Question: Need for Cohort 3 - Management believes it is essential to conduct Cohort 3 to fully assess the efficacy of three treatments, based on historical data suggesting that more treatments may yield better results [60] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company will need to conduct safety tests and treatments before integration with the Hemopurifier [45]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal third quarter ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call on February 12, 2026, at 4:30 p.m. ET, which will include a question and answer session [2] - Interested parties can register for the conference call online, and registered participants will receive a dial-in number [2] Group 2: Conference Call Access - For those without internet access, a toll-free number is available for participation in the conference call [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until March 12, 2026 [4] Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may have applications in cancer treatment [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]